320 related articles for article (PubMed ID: 31919669)
1. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
Gawade PL; Li S; Henry D; Smith N; Belani R; Kelsh MA; Bradbury BD
Support Care Cancer; 2020 Sep; 28(9):4413-4424. PubMed ID: 31919669
[TBL] [Abstract][Full Text] [Related]
2. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
4. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
Rifkin RM; Crawford J; Mahtani RL; Dale DC; Narang M; MacLaughlin WW; Huynh C; Gawade PL; Lewis S; DeCosta L; Lawrence T; Belani R
Support Care Cancer; 2022 Oct; 30(10):7913-7922. PubMed ID: 35732748
[TBL] [Abstract][Full Text] [Related]
5. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L; Baser O; Kutikova L; Page JH; Barron R
Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
[TBL] [Abstract][Full Text] [Related]
6. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
[TBL] [Abstract][Full Text] [Related]
7. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
8. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
[TBL] [Abstract][Full Text] [Related]
9. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
[TBL] [Abstract][Full Text] [Related]
10. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
Mahtani RL; Belani R; Crawford J; Dale D; DeCosta L; Gawade PL; Huynh C; Lawrence T; Lewis S; MacLaughlin WW; Narang M; Rifkin R
Support Care Cancer; 2022 Jul; 30(7):6135-6144. PubMed ID: 35426046
[TBL] [Abstract][Full Text] [Related]
11. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
16. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
[No Abstract] [Full Text] [Related]
17. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer.
Li S; Liu J; Gong T; Guo H; Gawade PL; Kelsh MA; Bradbury BD; Belani R; Lyman GH
J Geriatr Oncol; 2020 Nov; 11(8):1309-1315. PubMed ID: 32624415
[TBL] [Abstract][Full Text] [Related]
18. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Li S; Liu J; Guo H; Gawade PL; Kim C; Bensink ME; Chandler D
Support Care Cancer; 2020 Jun; 28(6):2637-2649. PubMed ID: 31624920
[TBL] [Abstract][Full Text] [Related]
19. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
Aapro MS; Chaplin S; Cornes P; Howe S; Link H; Koptelova N; Mehl A; Di Palma M; Schroader BK; Terkola R
Support Care Cancer; 2023 Sep; 31(10):581. PubMed ID: 37728795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]